Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
Albshesh A, Taylor J, Savarino EV, Truyens M, Armuzzi A, Ribaldone DG, Shitrit AB, Fibelman M, Molander P, Liefferinckx C, Nancey S, Korani M, Rutka M, Barreiro-de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, di Jiang C, Tepeš K, Coletta M, Foteinogiannopoulou K, Gisbert JP, Amir-Barak H, Attauabi M, Seidelin J, Afif W, Marinelli C, Lobaton T, Pugliese D, Maharshak N, Cremer A, Limdi JK, Molnár T, Otero-Alvarin B, Krznaric Z, Magro F, Karmiris K, Raine T, Drobne D, Koutroubakis I, Chaparro M, Yanai H, Burisch J, Kopylov U. Albshesh A, et al. Among authors: maharshak n. J Clin Med. 2021 Jun 29;10(13):2914. doi: 10.3390/jcm10132914. J Clin Med. 2021. PMID: 34209880 Free PMC article.
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. Kopylov U, et al. Among authors: maharshak n. Inflamm Bowel Dis. 2017 Mar;23(3):404-408. doi: 10.1097/MIB.0000000000001039. Inflamm Bowel Dis. 2017. PMID: 28178003
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Kopylov U, et al. Among authors: maharshak n. Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155. Inflamm Bowel Dis. 2018. PMID: 29788318
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.
Kopylov U, Avni-Biron I, Ron Y, Koslowsky B, Waterman M, Daher S, Ungar B, Schwartz D, Zittan E, Openhaim M, Yanai H, Maharshak N, Bar Gil Shitrit A, Naftali T, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. Kopylov U, et al. Among authors: maharshak n. Dig Liver Dis. 2019 Jan;51(1):68-74. doi: 10.1016/j.dld.2018.07.040. Epub 2018 Aug 10. Dig Liver Dis. 2019. PMID: 30172649 Clinical Trial.
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A, Ben-Ya'acov A, Siterman M, Waterman M, Hirsh A, Schwartz D, Zittan E, Adler Y, Koslowsky B, Avni-Biron I, Chowers Y, Ron Y, Israeli E, Ungar B, Yanai H, Maharshak N, Ben-Horin S, Eliakim R, Dotan I, Goldin E, Kopylov U. Bar-Gil Shitrit A, et al. Among authors: maharshak n. United European Gastroenterol J. 2020 May;8(4):418-424. doi: 10.1177/2050640620902956. Epub 2020 Jan 24. United European Gastroenterol J. 2020. PMID: 32213026 Free PMC article.
Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable.
Yanai H, Goren I, Godny L, Maharshak N, Ron Y, Avni Biron I, Leibovitzh H, Banai Eran H, Aharoni Golan M, Rabinowitz K, Ziv Baran T, Lavie I, Yadgar K, Zonensain K, Kopylov U, Ben Horin S, Eliakim R, Waterman M, Chowers Y, Ben-Shachar S, Dotan I; Israeli IBD Research Nucleus. Yanai H, et al. Among authors: maharshak n. Clin Gastroenterol Hepatol. 2021 Aug;19(8):1564-1572.e5. doi: 10.1016/j.cgh.2020.06.069. Epub 2020 Jul 3. Clin Gastroenterol Hepatol. 2021. PMID: 32629126
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.
Cohen NA, Plevris N, Kopylov U, Grinman A, Ungar B, Yanai H, Leibovitzh H, Isakov NF, Hirsch A, Ritter E, Ron Y, Shitrit AB, Goldin E, Dotan I, Horin SB, Lees CW, Maharshak N. Cohen NA, et al. Among authors: maharshak n. United European Gastroenterol J. 2020 Nov;8(9):1076-1085. doi: 10.1177/2050640620951400. Epub 2020 Aug 17. United European Gastroenterol J. 2020. PMID: 32807038 Free PMC article.
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, Wardi J, Zittan E, Ziv-Baran T, Abramas L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. Yanai H, et al. Among authors: maharshak n. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):49-59. doi: 10.1016/S2468-1253(21)00299-5. Epub 2021 Nov 2. Lancet Gastroenterol Hepatol. 2022. PMID: 34739863 Clinical Trial.
116 results